- Home
- IMAB vs ASRT Comparison
IMAB vs ASRT Comparison
Compare IMAB & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMAB
- ASRT
- Stock Information
- Founded
- IMAB 2014
- ASRT 1995
- Country
- IMAB United States
- ASRT United States
- Employees
- IMAB N/A
- ASRT N/A
- Industry
- IMAB Biotechnology: Pharmaceutical Preparations
- ASRT Biotechnology: Pharmaceutical Preparations
- Sector
- IMAB Health Care
- ASRT Health Care
- Exchange
- IMAB Nasdaq
- ASRT Nasdaq
- Market Cap
- IMAB 200.9M
- ASRT 57.9M
- IPO Year
- IMAB 2020
- ASRT 1997
- Fundamental
- Price
- IMAB $2.45
- ASRT $0.64
- Analyst Decision
- IMAB Strong Buy
- ASRT Strong Buy
- Analyst Count
- IMAB 2
- ASRT 2
- Target Price
- IMAB $6.00
- ASRT $3.25
- AVG Volume (30 Days)
- IMAB 1.2M
- ASRT 240.3K
- Earning Date
- IMAB 05-15-2025
- ASRT 08-06-2025
- Dividend Yield
- IMAB N/A
- ASRT N/A
- EPS Growth
- IMAB N/A
- ASRT N/A
- EPS
- IMAB N/A
- ASRT N/A
- Revenue
- IMAB N/A
- ASRT $119,001,000.00
- Revenue This Year
- IMAB N/A
- ASRT N/A
- Revenue Next Year
- IMAB N/A
- ASRT $11.91
- P/E Ratio
- IMAB N/A
- ASRT N/A
- Revenue Growth
- IMAB N/A
- ASRT N/A
- 52 Week Low
- IMAB $0.60
- ASRT $0.51
- 52 Week High
- IMAB $3.08
- ASRT $1.80
- Technical
- Relative Strength Index (RSI)
- IMAB 50.05
- ASRT 50.01
- Support Level
- IMAB $2.35
- ASRT $0.61
- Resistance Level
- IMAB $2.59
- ASRT $0.67
- Average True Range (ATR)
- IMAB 0.35
- ASRT 0.03
- MACD
- IMAB -0.06
- ASRT 0.00
- Stochastic Oscillator
- IMAB 1.86
- ASRT 62.50
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.